Adjuvant therapy in primary GIST: state-of-the-art

Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001.

(2017) C. L. Corless et al.   JOURNAL OF CLINICAL ONCOLOGY

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

(2012) Heikki Joensuu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Natural History of Imatinib-naive GISTs

(2011) Sabrina Rossi et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour – The impact of tumour rupture on patient outcomes

(2011) P. Rutkowski et al.   EJSO

Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor

(2011) J. Li et al.   EJSO

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts

(2011) Heikki Joensuu et al.   LANCET ONCOLOGY

Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study

(2010) J. Martin-Broto et al.   ANNALS OF ONCOLOGY

Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour

(2010) P. Hohenberger et al.   BRITISH JOURNAL OF SURGERY

Practical management of tyrosine kinase inhibitor-associated side effects in GIST

(2010) Heikki Joensuu et al.   CANCER TREATMENT REVIEWS

Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): An emerging role for drug blood level testing?

(2010) Margaret von Mehren et al.   CANCER TREATMENT REVIEWS

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis

(2009) Jason S Gold et al.   LANCET ONCOLOGY

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY

Surgical Margin Status and Prognosis of Gastrointestinal Stromal Tumor

(2008) António M. Gouveia et al.   WORLD JOURNAL OF SURGERY